User profiles for Itzel Bustos‐Villalobos
 | Itzel Bustos VillalobosAssistant Professor, Nagoya University Faculty of Medicine Verified email at med.nagoya-u.ac.jp Cited by 948 |
The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers
IR Eissa, I Bustos-Villalobos, T Ichinose, S Matsumura… - Cancers, 2018 - mdpi.com
Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene
laherparepvec (T-VEC, Imlygic ® ) was approved by the Food and Drug Administration (FDA) …
laherparepvec (T-VEC, Imlygic ® ) was approved by the Food and Drug Administration (FDA) …
Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation
IB Villalobos, Y Takahashi, Y Akatsuka… - Blood, The Journal …, 2010 - ashpublications.org
We investigated human leukocyte antigen (HLA) expression on leukemic cells derived from
patients at diagnosis and relapse after hematopoietic stem cell transplantation (HSCT) using …
patients at diagnosis and relapse after hematopoietic stem cell transplantation (HSCT) using …
[HTML][HTML] The impact of metformin on tumor-infiltrated immune cells: preclinical and clinical studies
…, S Matsumura, IR Eissa, I Bustos-Villalobos… - International Journal of …, 2023 - mdpi.com
The tumor microenvironment (TME) plays a pivotal role in the fate of cancer cells, and tumor-infiltrating
immune cells have emerged as key players in shaping this complex milieu. …
immune cells have emerged as key players in shaping this complex milieu. …
[PDF][PDF] Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials
IR Eissa, Y Naoe, I Bustos-Villalobos, T Ichinose… - Frontiers in …, 2017 - frontiersin.org
Oncolytic viruses (OVs) are opening new possibilities in cancer therapy with their unique
mechanism of selective replication within tumor cells and triggering of antitumor immune …
mechanism of selective replication within tumor cells and triggering of antitumor immune …
[HTML][HTML] Downregulation of GATA-2 and overexpression of adipogenic gene-PPARγ in mesenchymal stem cells from patients with aplastic anemia
…, M Tanaka, N Yoshida, IB Villalobos… - Experimental …, 2009 - Elsevier
Aplastic anemia (AA) is characterized by a reduced number of hematopoietic stem cells and
fatty replacement in the bone marrow. Transcriptional factor GATA-2 plays several important …
fatty replacement in the bone marrow. Transcriptional factor GATA-2 plays several important …
STING activator 2′ 3′‐cGAMP enhanced HSV‐1‐based oncolytic viral therapy
…, T Ichinose, I Bustos‐Villalobos… - Molecular …, 2024 - Wiley Online Library
Oncolytic viruses (OVs) can selectively replicate in tumor cells and remodel the microenvironment
of immunologically cold tumors, making them a promising strategy to evoke antitumor …
of immunologically cold tumors, making them a promising strategy to evoke antitumor …
[HTML][HTML] CD4+ virtual memory: Antigen-inexperienced T cells reside in the naïve, regulatory, and memory T cell compartments at similar frequencies, implications for …
…, G Luxardi, Y Miyamura, TD Yilma, IB Villalobos… - Journal of …, 2017 - Elsevier
It is widely accepted that central and effector memory CD4 + T cells originate from naïve T
cells after they have encountered their cognate antigen in the setting of appropriate co-…
cells after they have encountered their cognate antigen in the setting of appropriate co-…
Lack of CD4+CD25+FOXP3+ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease
…, Y Takahashi, Y Xu, K Akane, IB Villalobos… - European journal of …, 2013 - Springer
The aim of this study was to investigate changes in CD4 + CD25 + FOXP3 + regulatory T
cells (Tregs) throughout the clinical course of Kawasaki disease (KD) and correlations with …
cells (Tregs) throughout the clinical course of Kawasaki disease (KD) and correlations with …
Persistence of autoreactive IgA-secreting B cells despite multiple immunosuppressive medications including rituximab
Y He, M Shimoda, Y Ono, IB Villalobos, A Mitra… - JAMA …, 2015 - jamanetwork.com
Importance Immunobullous diseases mediated by IgA are often difficult to manage, but to
date no mechanism has been proposed. Rituximab is an anti-CD20 monoclonal antibody that …
date no mechanism has been proposed. Rituximab is an anti-CD20 monoclonal antibody that …
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
…, Y Naoe, S Matsumura, PA Sibal, I Bustos-Villalobos… - Scientific Reports, 2022 - nature.com
Oncolytic virus (OV) therapy is a promising cancer immunotherapy, especially for cold
tumors by inducing the direct lysis of cancer cells and initiation of potent antitumor response. …
tumors by inducing the direct lysis of cancer cells and initiation of potent antitumor response. …
